Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (Journal of Experimental & Clinical Cancer Research, (2023), 42, 1, (76), 10.1186/s13046-023-02649-6)

Christopher B. Cole, Maria Pia Morelli, Massimo Fantini*, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt, B. Brooke Solarz, Maria Fergusson, Sharon A. Mavroukakis, Anjum ZakiKwong Y. Tsang, Philip M. Arlen, Christina M. Annunziata*

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Fingerprint

Dive into the research topics of 'Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (Journal of Experimental & Clinical Cancer Research, (2023), 42, 1, (76), 10.1186/s13046-023-02649-6)'. Together they form a unique fingerprint.

Medicine & Life Sciences